Experimental and Therapeutic Medicine Special Issues

Antibiotic & Drug Discovery and Development

Lead Editor:

    Professor Vijaya Anand
    Bharathiar University

A long and exhausting screening of compounds that can act as modulators of a therapeutic target is required for drug discovery and development. This special issue will include articles and research on the "discovery and development of potential drugs" with a focus on proteins / enzymes as therapeutic targets that may be involved in the onset and progression of disease or a specific human infection. The journals in this special issue will present the most recent advances drug screening methods for identifying chemicals or natural compounds capable of effectively interacting with a target. In order to develop a drug suitable for clinical trials, therapy must be used. New strategies for drug discovery, design, and synthesis will be described in research articles. Chemical biology, also known as "chemistry-initiated biology," is an interdisciplinary field of study. Because all biological processes are the result of chemical events, chemical approaches can be used to comprehend and, in some cases, manipulate biological events. This rapidly expanding field of study will continue to open up new opportunities for future drug discovery and medical applications. The current special issue focuses on fundamental aspects of chemical biology: the development and application of "chemical probes" and "chemical tools" for the analysis and comprehension of biological events and disease states. significant in terms of paving the way for medical innovations and diagnostics The issue will include communications, full articles, and targeted reviews that will present recent advances in chemical biology in Asia. Over the last decade, antimicrobial resistance (AMR) has gotten a lot of attention throughout the world. The absence of antibiotics in the clinical pipeline is due to the lack of financial incentives for commercial development of antibiotics. As evidenced by the present COVID-19 problem, this has resulted in a perilous situation in which the widespread proliferation of highly resistant strains could jeopardise the global health system's viability. While a number of nonantibiotic alternative antimicrobial techniques show promise, it's hard to see how they'll be able to eliminate the need for new antibiotics in the near future. Small molecule inhibitors and probes, for example, hold a unique place in the arsenal of techniques for studying biological systems. They can be used to characterise the mechanistic and structural properties of individual proteins, as well as to interrogate the proteome of an entire organism. Chemical tools enable reversible, dose- and time-dependent interventions in a way that few other techniques can, as well as permanent labelling experiments in intact cells. They are effective tools for target identification and validation studies, and they can also serve as chemical starting points for antibiotic discovery. This Special Issue intends to highlight recent advances examples of chemical tools to address this challenge.

Submission deadline: 03 September 2022

The future of microbiota in human diseases: from diagnosis to treatments

Lead Editor:

    Professor Amedeo Amedei
    University of Florence

The microbiota, the trillions of microorganisms that live on and in humans, as well as the roles they may play in nutrition, sickness, cancer, and even brain development, have sparked a surge of interest in the last decade. Many scientists want to learn more about the microbiota so that we can use it to well define the pathogenesis of more human diseases and to improve the health. But different questions are currently open: how do we get there, and what challenges will we face along the way? What does microbial research have in store for the future? What is the future of microbiome research? What has to be done in order for this field to fulfil its potential? The idea of this special issue is to explore the innovative studies regarding the impacting role of microbiota in several human diseases and also its therapeutic approaches

Submission deadline: 16 August 2022

Novel advances in Interstitial Lung Diseases: From translational research to patient-centered care

Lead Editor:

    university of crete

ILDs are including mainly fibrotic chronic lung diseases affecting predominantly older adults, with a history of smoking. The current model of disease natural course is that recurrent injury of the alveolar epithelium in the context of advanced aging/cellular senescence is followed by defective re-epithelialization and scar tissue formation. Currently, two drugs, nintedanib and pirfenidone, that modify disease progression have been approved worldwide for the treatment of IPF. However, despite treatment, patients with fibrosis are not cured, and eventually, disease advances in most treated patients. Enhancing biogenomic and metabolic research output, its translation into clinical precision and optimal service delivery through patient-centeredness are key elements to support effective IPF care. In this issue, we will summarize therapeutic options currently investigated for fibrosis and sarcoidosis based on the major pathogenetic pathways and molecular targets that drive pulmonary fibrosis.

Submission deadline: 31 July 2022

Malignant transformation induced by environmental substances in several types of experimental cancer

Lead Editor:

    Dr Gloria m Calaf
    Universidad de Tarapaca. Instituto de Alta Investigacion

The interaction of chemical carcinogens with healthy cells associated with exogenous hormones can induce genomic damage and subsequently cause cancer with the ability of metastasize other tissues. The carcinogenesis process needs several mutational events to produce damage to the genome, and subsequent cell proliferation of these injured cells. DNA damage can be the result of interactions with exogenous agents such as chemical carcinogens. Examples are the organophosphorous pesticides that are chemical substances synthesized by men and mainly used for pest control in agriculture and residential urban surroundings. On the other hand, the estrogen 17β-estradiol is an endogenous hormone present in women that influences development, control of ovulation, implantation, fertilization and metabolism of minerals, carbohydrates, proteins and lipids. The production of endogenous estrogen ceases with menopause and there is a controversy concerning its use in hormone replacement therapy. There is strong epidemiological and clinical evidence that estrogens play a role in the induction, promotion and progression of a variety of cancers in target organs of rat, mice and hamster. Other studies have associated estrogen administration to postmenopausal women with an increased risk of endometrial and breast cancer. It will be of interest to put together information in relation to this subject in different types of cancers and the future avenue to understand mechanism to obtain new treatments.

Submission deadline: 25 January 2023

Translational research, techniques and innovation in GI endoscopy

Lead Editor:

    Dr Hajime Isomoto
    Department Gastroenterology and Nephrology, Tottori University

Recent advancement in GI endoscopic diagnostic yield and interventions has been outstanding by involvement by AI technology, robotics, innovative conceptions. Whilst, the invention has been supported by case series experience by experts even in certain sole case technical success or by translational research using animal models or basic research using the state-of-art technologies including omics. In this specific issues, we propose submission of full original communications related to topics above mentioned while case series experiences or informative case success if authors discuss potential prevalence of the novel techniques expanding to real world practice, insightful contrivance, or innovative concept that would open the door for breakthrough and foreseeable future perspective.

Submission deadline: 06 January 2023

Obesity related ailments: recent non invasive treatments

Lead Editor:

    Professor Marilena Vlachou
    National and Kapodistrian University of Athens

Obesity is a disease that leads to significant co-morbidities such as diabetes, fatty liver and cardiovascular disease, and significantly shortens a person's life expectancy and quality of life. There is a need for safer and more effective treatments for obesity, such as innovative drug delivery systems, vaccines, gut microbiota modification, and gene therapy. Novel delivery systems may include 3D printing technologies and the application of AI approaches. Novel drugs, such as combinations of gastrointestinal hormones and other agents, are being explored and, when available, are expected to lead to significant weight loss with fewer side effects.

Submission deadline: 30 December 2022

Hemophagocytic lymphohistiocytosis

Lead Editor:

    Dr Fabio Timeus
    Ospedale Infantile Regina Margherita. Pediatric Onco-Hematology.

Hemophagocytic lymphohistiocytosis (HLH) is characterized by an uncontrolled immune response upon exposure to various triggers. A common feature is the severity of the clinical picture caused by the cytokine storm, and the ominous outcome in the absence of early diagnosis and treatment. Familial forms typically affect childhood, but manifestations of onset in adulthood are possible. Malignancies and infections can cause secondary forms, not related to hereditary defects. There are close affinities between HLH and macrophage activation syndrome (MAS), sometimes observed at the onset or in the course of autoimmune diseases. The clinical picture of HLH can be confused with that of sepsis. This suggests interesting problems of differential diagnosis and pathophysiology. Hematopoietic stem cell transplantation has a central role in the therapy of familiar forms. Misdiagnosis or late diagnosis of HLH is not rare and a better knowledge of this pathology is necessary to improve its prognosis. New aspects of this topic are the forms secondary to immunotherapy, the role of monoalleic mutations, the anti-cytokine therapies.

Submission deadline: 29 December 2022

Congenital Growth and Development Defects

Lead Editor:

    Dr Qiang Huang
    Duke University
    United States

Congenital growth and developmental defects are mainly caused by congenital malformations, which are structural or functional anomalies occurring as the fetus is growing within its mother’s womb. They are caused by genetic, infectious, nutritional, or environmental factors. There is no specific therapy for these defects, even though some have existing therapeutic methods, such as surgeries, vaccination, specific medicine. Many therapeutic methods are in development, such as gene editing and stem cell therapy. In this special issue, we will talk about the defect-related aspects, including experimental models, the development of therapeutic methods (including surgeries in development), etiology, diagnosis, and prevention. We invite review and original research papers related, but not limited, to the above topics in order to realize a special issue that will further the defect medicine.

Submission deadline: 24 December 2022

Journal Cover

Volume 24 Issue 2

Print ISSN: 1792-0981
Online ISSN: 1792-1015

Sign up for eToc alerts

Recommend to Library

Full Size Image